Tonbo Imaging India’s ₹852.18 crore IPO entered its final day of subscription on October 16, 2026, with the price band set at ₹665 to ₹700 per share. The issue was subscribed 10.33 times as of 10:12 AM on Day 3.
The basis of allotment is expected to be finalised on October 21, while the company’s shares are scheduled to list on the BSE and NSE on October 23, 2026, subject to the proposed timeline.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
15 October 2026 |
|
Subscription Closing Date |
19 October 2026 |
|
Basis of Allotment Date |
21 October 2026 |
|
Refund Initiation Date |
22 October 2026 |
|
Credit of Shares |
22 October 2026 |
|
Listing on BSE and NSE |
23 October 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[October 19, 2026, 10:12 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
3.96x |
|
Non-Institutional Investors (NIIs) |
23.38x |
|
Retail Individual Investors (RIIs) |
8.36x |
|
Employees |
14.84x |
|
Total |
10.33x |
Established in 2003, Tonbo Imaging India Limited develops and manufactures defence electronics, specialising in thermal imaging, surveillance, target acquisition and missile guidance systems. Its products use electro-optics, infrared imaging and embedded vision technologies for defence applications in India and overseas. As of June 30, 2026, the company had deployed over 28,000 systems across 24 countries. Its electro-optical and infrared (EO/IR) products are not subject to US International Traffic in Arms Regulations (ITAR), providing greater flexibility in international trade, subject to applicable export-control requirements.
|
Particulars |
For the three month period ended June 30, 2026 (in ₹ crore) |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
|
Revenue from operations |
36.01 |
362.65 |
469.08 |
|
EBITDA |
(13.04) |
104.62 |
139.06 |
|
Profit After Tax (PAT) |
(17.74) |
50.89 |
72.76 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here